Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

BusinessWeek February 12, 2007 Bruce Einhorn	Stem-Cell Refugees Americans are flocking to China for therapy.
Fast Company December 2009 Erica Westly	The Price of Winning FDA Approval Approval for a new drug or medical treatment requires extensive -- and expensive -- human trials for safety and effectiveness.
The Motley Fool April 14, 2008 Brian Orelli	Stem Cells Show Off The FDA moves closer to setting up stem cell clinical trials, setting guidelines that put treatment safety first and foremost.
Reason Aug/Sep 2007 Kerry Howley	Dying for Lifesaving Drugs Will desperate patients destroy the pharmaceutical system that produces tomorrow's treatments?
Pharmaceutical Executive November 1, 2012 Sue Barrowcliffe	Real World Insights Commercial teams as well as patients can benefit from managed access programs, which are designed to provide access to medicines outside of the clinical and commercial setting, for patients who have no other available treatment options.
The Motley Fool October 22, 2010 Luke Timmerman	Aastrom Maps Out Pivotal Trial Strategy With Adult Stem Cell Therapy Aastrom needs a good strategy for working with U.S. drug regulators.
BusinessWeek June 13, 2005 Catherine Arnst	Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins.
The Motley Fool May 17, 2010 Luke Timmerman	Vertex Awaits Final Proof that Hepatitis C Drug Works For this drug researcher, the proof is in the telaprevir.
Pharmaceutical Executive October 1, 2012 Ben Comer	Stem Cells: A Promise Deferred? Ideology, politics, and a stilted political debate may be causing pharma to overlook the potential of emerging stem cell therapies in fostering a new generation of cures.
The Motley Fool August 9, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
The Motley Fool September 20, 2005 Rich Smith	ViaCell's Cancer Trial Snag The cord blood collector suffers a research setback. Investors should keep in mind that the real money-maker behind ViaCell is its ViaCord cord blood storage business.
The Motley Fool March 1, 2007 Brian Lawler	Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works.
The Motley Fool July 30, 2007 Brian Orelli	Another Blow to Gene Therapy The FDA shuts down a clinical trial, tripping up Targeted Genetics and possibly its competitors. A subject in the trial of their gene therapy arthritis medication died shortly after taking the drug.
The Motley Fool August 20, 2011 Luke Timmerman	Seattle Genetics Wins FDA Approval of First Drug FDA gives a quick turnaround on the new treatment for lymphomas.
BusinessWeek May 24, 2004 Arlene Weintraub	Repairing The Engines Of Life Can research into stem cells and other advanced techniques heal ailing hearts and brains? U.S. labs are hamstrung by the federal government.
The Motley Fool May 15, 2007 Mike Havrilla	Secret Cytori Cytori may be a lesser-known player in the stem-cell therapy field, but it's a stock to watch in the coming year.
AskMen.com Joshua Levine	Selling Your Body To Science Have you ever thought about the number of voluntary patients who basically sell their bodies to clinical trials in the name of science? Well, the number is staggering and it can reach well into the thousands. The main reason being the large paycheck that comes with the job.
Pharmaceutical Executive June 1, 2014 Jill Wechsler	Compassionate Use Requests Complicate Drug Development Pharma, HCPs, and regulators walk tightrope in addressing early-access push while supporting biomedical R&D.
Reason October 2007 Ronald Bailey	Is Industry-Funded Science Killing You? The overrated risks and underrated benefits of pharmaceutical research "conflicts of interest."
Pharmaceutical Executive July 1, 2011 Dickmeyer & Rosenbeck	From Rut to Racetrack Can the pharmaceutical industry deliver on its objective to make cancer a curable, chronic condition?
The Motley Fool July 27, 2011 Alexander Crawford	Vertex Moving Closer to a Cure for Hepatitis C How do you think the treatment of hepatitis C will evolve?
Wired March 2006 Jennifer Kahn	A Nation of Guinea Pigs There's a new outsourcing boom in South Asia - and a billion people are jockeying for the jobs. How India became the global hot spot for drug trials.
Pharmaceutical Executive April 1, 2011	Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help.
The Motley Fool August 2, 2010 Brian Orelli	Back in Love With Geron Investors' love / hate relationship with Geron is back in the worship phase, with the stem cells company up 17% on Friday and nearly an additional 10% or so today.
The Motley Fool September 7, 2010 Luke Timmerman	Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too.
Scientific American January 17, 2007 Charles Q. Choi	A Stroke for Stem Cells The brain becomes a target in stem cell clinical trials.
BusinessWeek February 10, 2011 Rob Waters	Sangamo's Bet Against AIDS: Gene Therapy Sangamo's stock has more than doubled since July 6, when the company, with no products on the market, reported success of its gene therapy approach in mice in the journal Nature Biotechnology.
The Motley Fool December 31, 2011 Brian Orelli	3 Stock-Moving Binary Events to Watch in 2012 Binary events, FDA decisions, and clinical trial results, are the lifeblood -- and death wish -- of the biotech industry. Here are three to watch in 2012.
The Motley Fool September 13, 2007 Brian Orelli	Alfacell's Awkward Wait Waiting for subjects to die is a somber part of the oncology clinical trial process. Alfacell is doing just that in its final phase three trial with its lead cancer drug candidate. Investors take note.
Investment Advisor December 2005 Greg B. Scott	Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns.
Pharmaceutical Executive April 1, 2012 Feam & Lagus	Providing Access Now While regulatory frameworks and medical practices differ between countries, many patients still need early access to new drugs. Industry can help.
BusinessWeek May 28, 2007 Bruce Einhorn	The Rush To Test Drugs In China Despite ethical concerns, Big Pharma is recruiting more patients for clinical trials in China.
Managed Care June 2007 Thomas Morrow	Dendritic Cell Vaccine Hits FDA Roadblock Questions about study design and analysis prompted the FDA to postpone action on Provenge, a treatment for advanced prostate cancer.
The Motley Fool November 9, 2004 Charly Travers	Are Stem Cells a Rule Breaker? Does the science offer real hope or just hype? Biotech investors take on enough risk in the normal course of drug development that they do not need to worry about whether or not the underlying technology even works.
Bio-IT World August 13, 2002 Mark D. Uehling	Clinical Trial Data Management: Tortured by Paper Reams of paper stuffed into boxes and shipped to the FDA by the truckload is hardly the best approach to drug approval. But what's the right way?
Pharmaceutical Executive July 1, 2006 Derek Lowe	What You Need to Know About Adaptive Trials A handful of new statistical techniques and clinical-trial designs will let you change the way you run your business. Here's your guide to the basics.
The Motley Fool January 3, 2011 Brian Orelli	Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure.
The Motley Fool June 17, 2010 Luke Timmerman	Oncothyreon's Cancer Vaccine Back in the Saddle as Merck KGaA Re-Starts Clinical Trials The German-based Merck got clearance from the FDA and local ethics review boards to resume two of three large pivotal trials.
HHMI Bulletin Aug 2011	Seeing is Believing Today, researchers are finding clever ways to deliver long-lasting, healthy genes without triggering a serious immune response.
Registered Rep. February 1, 2005 Bob Hirschfeld	Healing Investments New lung cancer drugs mean good news in both the doctor's office and on Wall Street.
BusinessWeek June 13, 2005 Arlene Weintraub	A Boost for Broken Hearts? The Institute of Regenerative Medicine in Barbados is convinced that stem cells from fetuses can repair cardiac damage.
The Motley Fool June 29, 2007 Brian Orelli	The Phase 2 Blues Drug developer Cytokinetics disappoints investors with failed clinical trials.
BusinessWeek March 6, 2006 Bruce Einhorn	A Cancer Treatment You Can't Get Here China, with lower regulatory hurdles, is racing to a lead in gene therapy.
BusinessWeek July 18, 2005 John Carey	Is Heart Surgery Worth It? Physicians are questioning whether bypasses and angioplasties necessarily prolong patients' lives.
The Motley Fool June 2, 2004 Brian Gorman	New Injection for Genzyme A partnership with Medtronic bolsters Genzyme's myoblast cell therapy program.
The Motley Fool November 14, 2011 Brian Orelli	Biotech Uncertainty = Big Upside Potential Aastrom's phase 2 and phase 3 trials don't match up.
The Motley Fool July 25, 2007 Brian Orelli	On to the FDA With a New Name After four phase 3 clinical trials, Advanced Magnetics is ready to submit a New Drug Application for ferumoxytol, and if all goes well, could have the product on the market by the end of next year.
Pharmaceutical Executive October 1, 2008 Joanna Breitstein	The D-Mab Men Amgen's salvation just may be denosumab. We sit down to talk with the head scientists driving the drug for the multi-billion dollar osteoporosis market
BusinessWeek June 27, 2005 Arlene Weintraub	Stem Cells To Go ViaCell's goal is to mass-produce stem cells from umbilical cord blood.
Pharmaceutical Executive November 1, 2014 Josh Baxt	2015 Pipeline Report: Burning Bright The science of drug discovery is back on script and the stars are cued up for a new generation of breakthrough therapies.